Abstract
To provide a review of the two pivotal clinical trials evaluating trastuzumab in metastatic breast cancer, either in combination with chemotherapy or as a single agent. Research reports. Trastuzumab is indicated as a single agent or in combination with chemotherapy for patients with metastatic breast cancer who overexpress the HER2 protein. The toxicity profile of trastuzumab is favorable; cardiac dysfunction has been the primary dose-limiting toxicity, especially when combined with anthracyclines. Nurses will deliver trastuzumab in the clinical setting and must be familiar with its efficacy and toxicity profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
